NLRP3 and Schnitzler syndrome: This was most prominent in treatment‐resistant patients from cohort AOSD#3 who also had higher ASC/NLRP3 specks in comparison with patients with AIDs typically associated with NLRP3 inflammasome activation, such as cryopyrin‐associated periodic syndrome (CAPS) and Schnitzler syndrome (Figure 4A).